Allosteric ALK2 Inhibitors for Selective Protein Destabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds that inhibit ALK2 kinase also affect other kinases, making them unsuitable for clinical use in treating disorders like Fibrodysplasia Ossificans Progressiva, which requires specific inhibition of ALK2 without affecting other kinases.
Innovation Solution
Identifying and developing compounds that bind to an allosteric site of ALK2, rather than the active site, to destabilize the protein, using a method that involves screening for molecules capable of binding to a specific location adjacent to a regulatory subdomain, allowing for selective inhibition through macrocyclic compounds that form covalent linkages or hydrogen bonds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds bind to the active site of ALK2 kinase, then inhibition of ALK2 activity is achieved, but selectivity is reduced and other kinases are affected
Solution Approach 1:
The patent transitions from binding at the conserved active site (one-dimensional competition) to binding at an allosteric site (another dimension), achieving inhibition through a different spatial and mechanistic approach. This dimensional shift allows selective inhibition of ALK2 without affecting other kinases that share the conserved active site structure.
Solution Approach 2:
The invention targets a specific local region (allosteric site adjacent to the regulatory subdomain) rather than the general active site. This localized binding approach exploits unique structural features of ALK2 at this specific location, providing selectivity while maintaining inhibition efficacy.
2Adaptability or versatility
If compounds bind to the conserved ATP-binding cleft, then broad kinase inhibition is achieved, but ALK2-specific inhibition is reduced
Solution Approach 1:
The patent moves from binding at the conserved ATP-binding cleft to binding at an allosteric site, changing the dimension of interaction from a universally conserved region to a kinase-specific region. This enables ALK2-specific inhibition while maintaining the ability to achieve broad inhibition through rational drug design.
Solution Approach 2:
The invention focuses on a specific local structure (allosteric site with unique structural features) rather than the general ATP-binding cleft. This localized approach provides ALK2-specific recognition and inhibition, improving reliability for treating FOP while avoiding broad off-target effects.
3Object-generated harmful factors
If allosteric inhibitors are used to achieve selectivity, then off-target effects are reduced, but binding mechanism complexity increases
Solution Approach 1:
The allosteric inhibitor acts as an intermediary that indirectly affects ALK2 activity by binding at a site distant from the active site. This intermediary mechanism provides selectivity by exploiting unique structural features at the allosteric site, reducing off-target effects while the complexity is managed through rational drug design based on structural insights.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The allosteric inhibitors effectively destabilize the ALK2 kinase, reducing its activity and stability, potentially preventing the progression of FOP and other diseases associated with ALK2 mutations, while minimizing side effects on other kinases, and can be administered prophylactically to target soft tissues only upon trauma, avoiding muscle wasting or heterotopic bone formation.
Implementation Method 1
The present invention provides a useful method for the identification of putative inhibitors of activin-like receptor kinases that destabilize the proteins by binding at a site other than the highly conserved ATP-binding cleft or active site.
Data Source
AI summary
The claimed invention is directed to a method for screening a compound that binds to an allosteric site of ALK2, the method comprising screening for a compound that is capable of destabilizing the ALK2 protein. A further aspect of the invention is directed to a pharmaceutical composition for the treatment and/or prophylaxis of a disease in a vertebrate, said composition comprising at least one ALK receptor kinase inhibitor, and optionally a pharmaceutically acceptable carrier, adjuvant and/or diluent.